Literature DB >> 28291641

Long-term treatment with interferon alfa for myeloproliferative neoplasms.

Jean-Jacques Kiladjian1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28291641     DOI： 10.1016/S2352-3026(17)30039-X

Source DB:  PubMed          Journal:  Lancet Haematol        ISSN： 2352-3026            Impact factor:   18.959


× No keyword cloud information.
  3 in total

Review 1.  Running interferon interference in treating PV/ET: meeting unmet needs.

Authors:  Elizabeth A Traxler; Elizabeth O Hexner
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera.

Authors:  Roland Jäger; Heinz Gisslinger; Elisabeth Fuchs; Edith Bogner; Jelena D Milosevic Feenstra; Jakob Weinzierl; Fiorella Schischlik; Bettina Gisslinger; Martin Schalling; Michael Zörer; Kurt Krejcy; Christoph Klade; Robert Kralovics
Journal:  Blood       Date:  2021-01-21       Impact factor: 22.113

3.  Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo.

Authors:  Emmanuelle Verger; Juliette Soret-Dulphy; Nabih Maslah; Lydia Roy; Jerome Rey; Zineb Ghrieb; Robert Kralovics; Heinz Gisslinger; Barbara Grohmann-Izay; Christoph Klade; Christine Chomienne; Stéphane Giraudier; Bruno Cassinat; Jean-Jacques Kiladjian
Journal:  Blood Cancer J       Date:  2018-10-04       Impact factor: 11.037
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.